两种新的选择性环氧合酶-2抑制剂

被引：34

作者：

陈望忠

机构：

[1] 军事医学科学院毒物药物研究所!北京

来源：

国外医学药学分册. | 1997年 / 03期

关键词：

环氧合酶-1; 环氧合酶-2; 美洛昔康; 氯诺昔康;

D O I：

10.13220/j.cnki.jipr.1997.03.011

中图分类号：

R979.5 [免疫增强剂、免疫抑制剂];

学科分类号：

1007 ;

摘要：

选择性环氧合酶 2 (COX 2 )抑制剂已成为寻找副作用小的、非甾体类抗炎药的研究方向。美洛昔康与氯诺昔康是两种结构不同的昔康类非甾体抗炎药 ,所具有的消炎镇痛作用及良好的胃肠道耐受性与它们对COX 2的选择性抑制作用有关。本文报道了美洛昔康和氯诺昔康对COX 2的选择性抑制作用及相应的药效学和药动学性质。

引用

页码：168 / 171

页数：4

共 21 条

[11]

Pharmacokinetics and tolerability of meloxicam after i.m. administration. Narjes H,Turck D,Busch U,et al. British Journal of Clinical Pharmacology . 1996

[12]

Clinical pharmacokinetics of meloxicam. Turck D,Busch U,Heinzel G et al. European Journal of Rheumatology and Inflammation . 1996

[13]

Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Engelhardt G,Homma D,Schnitzler C. Inflammation Research . 1995

[14]

Melocicam: a new NSAID with an improved safety profile through preferential inhibition of COX-2. Engelhardt G,Bogel R,Schnitzler C,et al. Biochemical Pharmacology . 1996

[15]

Enzyme structures could improve pain relievers. Borman S. Chemical and Engineering News . 1996

[16]

The X-ray crystal structure of the membrane protein prostaglandin H2 synthase1. Picot D,Loll PJ,Garavito RM. Nature . 1994

[17]

Theeffectofmeloxicamonthepharmacokineticsofβ acetyl digoxin. DegnerFL,HeinzelG,NarjesH ,etal. BrJClinPharmacol . 1 995

[18]

Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Ilias W,Jansen M. British Journal of Clinical Practice . 1996

[19]

Gastrointe- stinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aabakken L,Osnes M,Frenzel W. Alimentary Pharmacology and Therapeutics . 1996

[20]

Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Pruss TP,Stroissnig H,Radhofer-Welte S,et al. Postgraduate Medical Journal .

← 1 2 3 →